regdanvimab (Regkirona- CT-P59-Celltrion) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
CT-P59 3.2 part 1 NCT04602000		RCT	regdanvimab (Regkirona- CT-P59-Celltrion)	placebo	COVID 19 outpatients	NA	226/111	inconclusive
CT-P59 3.2 part 2 NCT04602000		RCT	regdanvimab (Regkirona- CT-P59-Celltrion)	placebo	COVID 19 outpatients	NA	656/659	conclusif	demonstrated 71 % decrease in hospitalization or death (PE) suggested 50 % increase in clinical improvement (time to event analysis only),Recovery (time to event analysis only)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis